Meeting
2013 ASCO Annual Meeting
EGFR and KRAS mutations during anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer: Clinically relevant?
Authors
Lucie Karayan-Tapon
Department of Molecular Oncology, Poitiers, France
Lucie Karayan-Tapon , Aurelie Ferru , Ulrich Cortes , Claire Villalva , Jean Marc Tourani , Christine Silvain , Pierre Levillain , David Tougeron
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3513)
DOI
10.1200/jco.2013.31.15_suppl.3513
Abstract #
3513
Poster Bd #
5
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
Prevalence of KRAS, BRAF, NRAS, PIK3CA, and PTEN alterations in colorectal cancer: Analysis of a large international cohort of 5,900 patients.
First Author: Gargi Dan Basu
Poster
2013 ASCO Annual Meeting
Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies.
First Author: M. Pia Morelli
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of acquired RAS, BRAF and PIK3CA mutation at 8 weeks on the efficacy of anti-EGFR monoclonal antibodies in metastatic colorectal cancer.
First Author: Takeshi Yamada
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Panitumumab plus trifluridine/tipiracil as third-line anti-EGFR rechallenge therapy in chemo-refractory RAS WT metastatic colorectal cancer: The VELO randomized phase II clinical trial.
First Author: Stefania Napolitano